Wipfli Financial Advisors LLC acquired a new position in shares of Organon & Co. (NYSE:OGN – Get Rating) during the third quarter, Holdings Channel reports. The institutional investor acquired 1,203 shares of the company’s stock, valued at approximately $28,000.
Other large investors have also recently made changes to their positions in the company. Investors Asset Management of Georgia Inc. GA ADV acquired a new stake in Organon & Co. during the second quarter valued at $25,000. CoreCap Advisors LLC purchased a new position in shares of Organon & Co. in the 2nd quarter valued at about $27,000. ACG Wealth acquired a new position in Organon & Co. in the 2nd quarter worth about $31,000. Truvestments Capital LLC purchased a new position in Organon & Co. during the second quarter worth approximately $33,000. Finally, Coston McIsaac & Partners acquired a new stake in Organon & Co. in the second quarter valued at approximately $33,000. 75.74% of the stock is currently owned by institutional investors and hedge funds.
Organon & Co. Price Performance
Shares of NYSE:OGN opened at $31.34 on Friday. Organon & Co. has a 1 year low of $22.88 and a 1 year high of $39.47. The firm has a market capitalization of $7.97 billion, a PE ratio of 7.91 and a beta of 0.71. The business’s 50 day moving average price is $27.63 and its 200-day moving average price is $28.10.
Organon & Co. Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Thursday, December 15th. Stockholders of record on Monday, November 14th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend was Thursday, November 10th. Organon & Co.’s dividend payout ratio is currently 28.28%.
Analyst Ratings Changes
Several research analysts have recently weighed in on the company. Bank of America downgraded Organon & Co. from a “neutral” rating to an “underperform” rating and set a $25.00 target price for the company. in a research note on Friday, October 14th. Morgan Stanley decreased their price objective on shares of Organon & Co. from $27.00 to $24.00 and set an “equal weight” rating on the stock in a report on Friday, November 4th.
Organon & Co. Profile
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
- Get a free copy of the StockNews.com research report on Organon & Co. (OGN)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.